Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (26)

2024

  1. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

2023

  1. Learning Curve for Ultrasound Assessment of Myometrial Infiltration in Endometrial Cancer Visualizing Videoclips: Potential Implications for Training

    Diagnostics, Vol. 13, Núm. 3

2022

  1. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

    Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43

  2. Nutrition in palliative care: guidelines from the Working Group on Bioethics, Spanish Society of Clinical Nutrition and Metabolism (SENPE)

    Nutricion Hospitalaria, Vol. 39, Núm. 4, pp. 936-944

  3. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study

    BMC Cancer, Vol. 22, Núm. 1

  4. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Characteristics of isolated superficial vein thrombosis and diagnostic-therapeutic management in spanish hospital emergency departments:The altamira study

    Emergencias, Vol. 33, Núm. 6, pp. 433-440

  2. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2020

  1. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  2. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

    Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Nutrición parenteral domiciliaria en españa 2016; informe del grupo de nutrición artificial domiciliaria y ambulatoria nadya

    Nutricion Hospitalaria, Vol. 34, Núm. 6, pp. 1497-1501

  3. Registro del Grupo NADYA-SENPE de nutrición enteral domiciliaria en España, años 2014 y 2015

    Nutricion Hospitalaria, Vol. 34, Núm. 1, pp. 15-18

  4. The utility of Next Generation Sequencing for molecular diagnostics in Rett syndrome

    Scientific Reports, Vol. 7, Núm. 1

  5. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

  2. Home Parenteral Nutrition in Spain, 2015. Home and Ambulatory Artificial Nutrition (NADYA) Group report

    Nutricion Hospitalaria, Vol. 33, Núm. 6, pp. 1487-1490

  3. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2011

  1. Prevention of venous thromboembolism in patients with cancer in Spain

    Journal of Coagulation Disorders, Vol. 3, Núm. 1, pp. 64-68